NCT04661696 Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. Status UNKNOWN Phase PHASE2
NCT04657068 A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT04644068 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT04640480 Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors Status COMPLETED Phase PHASE1
NCT04630327 Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory Status COMPLETED Phase N/A
NCT04626895 Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers Status COMPLETED Phase NA
NCT04625270 A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04617470 Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study Status UNKNOWN Phase N/A
NCT04614051 Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) Status TERMINATED Phase PHASE1
NCT04608409 Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer Status COMPLETED Phase PHASE1
NCT04606914 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Status RECRUITING Phase PHASE2
NCT04602117 ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Status WITHDRAWN Phase PHASE1
NCT04590625 Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer Status UNKNOWN Phase PHASE2
NCT04590326 A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab Status RECRUITING Phase PHASE1/PHASE2
NCT04586335 Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Status TERMINATED Phase PHASE1
NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Status RECRUITING Phase PHASE1/PHASE2
NCT04582552 The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer Status UNKNOWN Phase N/A
NCT04580485 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors Status COMPLETED Phase PHASE1